18F-FDG PET/CT seems to be an accurate method for detection and localization of local and distant recurrence in GIST with good sensitivity and specificity and significant impact on clinical decision-making.
This was a 2-stage, phase 2 trial investigating dasatinib 2 × 70 mg per day in patients with histologically proven, TKI-naïve, FDG-PET/CT-positive GIST.
<b>Conclusion:</b> Performing <sup>18</sup>F-FDG PET for early evaluation of response often results in a change of management in GIST patients harboring the non-<i>KIT</i> exon 11 mutation and should be considered the standard of care in GIST patients treated with neoadjuvant intent.